All In Biotech

NDA 021856 · Takeda Pharms USA

Uloric

Febuxostat · Oral · Xanthine Oxidase Inhibitor

Novel

Last checked: Nov 20, 2026Latest source record: Apr 17, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2009

Feb 13, 2009

Approved uses

3

Original approval plus efficacy supplements

Registered trials

108

21 Phase 3, 9 recruiting

FAERS reports

17,000

12,910 serious, 2,242 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: CARDIOVASCULAR DEATH Gout patients with established cardiovascular (CV) disease treated with ULORIC had a higher rate of CV death compared to those treated with allopurinol in a CV outcomes study [see Warnings and Precautions (5.1) ] . Consider the risks and benefits of ULORIC when deciding to prescribe or continue patients on ULORIC. ULORIC should only be used in patients who have an inadequate response to a maximally titrated dose of allopurinol, who are intolerant to allopurinol, or for whom treatment with allopurinol is not advisable [see Indications and Usage (1) ] . WARNING: CARDIOVASCULAR DEATH See full prescribing information for complete boxed warning. Gout patients with established cardiovascular (CV) disease treated with ULORIC had a higher rate of CV death compared to those treated with allopurinol in a CV outcomes study. ( 5.1 ) Consider the risks and benefits of...

What it is approved for

From the label in effect Dec 24, 2025.

ULORIC is a xanthine oxidase (XO) inhibitor indicated for the chronic management of hyperuricemia in adult patients with gout who have an inadequate response to a maximally titrated dose of allopurinol, who are intolerant to allopurinol, or for whom treatment with allopurinol is not advisable. ULORIC is a xanthine oxidase (XO) inhibitor indicated for the chronic management of hyperuricemia in adult patients with gout who have an inadequate response to a maximally titrated dose of allopurinol, who are intolerant to allopurinol, or for whom treatment with allopurinol is not advisable. ( 1 ) Limitations of Use : ULORIC is not recommended for the treatment of asymptomatic hyperuricemia. ( 1 ) Limitations of Use : ULORIC is not recommended for the treatment of asymptomatic hyperuricemia.

Mechanism: ULORIC, a xanthine oxidase inhibitor, achieves its therapeutic effect by decreasing serum uric acid. ULORIC is not expected to inhibit other enzymes involved in purine and pyrimidine synthesis and metabolism at therapeutic concentrations.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • ULORIC · FEBUXOSTAT 80MG · TABLET, ORAL · Prescription · TE AB
  • ULORIC · FEBUXOSTAT 40MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Febuxostat" as an intervention, any sponsor and status, largest first.

All 108 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • diarrhoea904
  • acute kidney injury881
  • nausea870
  • rash812
  • off label use772
  • drug ineffective709
  • gout700
  • dyspnoea651
  • fatigue628
  • headache599
  • anaemia598
  • pneumonia569

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200973
2010105
2011196
2012226
2013294
2014356
20152,414
2016863
2017867
20181,045
20191,142
20201,165
20211,431
20221,668
20231,474
20241,466
20251,325
2026890

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Uloric (Febuxostat)

2024 spending

$4.1M

Beneficiaries

1,723

7,458 claims

Per beneficiary

$2,398

$10.32 per unit

View as table
YearSpending
2020$17,641,167
2021$10,402,721
2022$7,851,519
2023$6,049,573
2024$4,132,481

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 257 on PubMed

Sponsor: Takeda

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.